5302392025-07-012025-09-305302392025-09-305302392025-03-315302392025-04-012025-09-305302392025-07-012025-09-30in-capmkt:OtherExpenses1Member5302392025-07-012025-09-30in-capmkt:OtherExpenses2Member5302392025-04-012025-09-30in-capmkt:OtherExpenses1Member5302392025-04-012025-09-30in-capmkt:OtherExpenses2Member5302392025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15302392025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares530239SUVENNOTLISTEDINE495B01038SUVEN LIFE SCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312025-11-112025-11-03INRLakhsQuarterlySecond quarterSingle segmentThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented2025-11-1111:30:002025-11-1112:05:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated9192000377800004697200000060765000013168000746138000820071000-7730990000-7730990000000-7730990000000-773099000852000-77224700000002274740001-3.48-3.4800-3.48-3.48 <BR> 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2025. The results for the quarter ended September 30, 2025 has been reviewed by our statutory auditors <BR> <BR> 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc <BR> 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <BR> 5) ESOP:For the quarter ended September 2025, the Company recognized an employee benefit expense (EBP) of Rs. 26.35 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of September 2025 amounts to Rs.53.73 lakhs. During the quarter, out of 2,21,800 options under the 1st tranche, 2,14,000 options were exercised, and the Company received 117.70 lakhs pursuant to the exercise of employee stock options under its ESOP scheme. As of the reporting date, the equity shares corresponding to these exercised options had been allotted on 24.07.2025. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees, as the vesting period extends until 06-May-2027. <BR> 6) Preferential Issue : The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. <BR> Each warrant is convertible into one equity share of face value Rs. 1 at an exercise price of Rs. 134 per share, within a period of 18 months from the date of allotment. <BR> During the quarter the Company has alloted 9186490 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants (allotted on 16.07.2025) to three allottees, upon receipt of 100% of the warrant consideration amounting to Rs.12,309.90 lakhs. <BR> <BR> Break-up of the amounts received is as follows: <BR> <BR> Particulars Amount in Lakhs <BR> 25% upfront received from 23 allottees 21,441.01 <BR> Balance 75% received from 3 allottees 9,232.42 <BR> Total money received as on 30th September 2025 30,673.43 <BR> <BR> Summary of Utilisation of Proceeds of Preferential issue as on 30.09.2025 <BR> <BR> Particulars Amount Rs.In lakhs <BR> Amout Received through Preferential Issue 30673.43 <BR> Less: Amount Utilised -5424.12 <BR> Balance Amount 25249.31 <BR> <BR> <BR> 7) The corresponding previous period figures have been regrouped / reclassified where ever necessary. <BR> 2025-04-012025-09-30UnauditedConsolidated27859000437780007163700000012052100002685200012125320001359905000-12882680000-12882680000000-12882680000000-1288268000340000-128792800000002274740001-5.8-5.800-5.8-5.8R & D Expenses703213000Other Expenses42925000R & D Expenses1118097000Other Expenses94435000580563000869000000189300000000058600058600007120005924440002404000246712600010677000960930001177000001007100025957370001374200016977300027816560000033741000002274740002585267000281274100002812741000000001710500000017105000058160004461000050426000460083000510509000026905000684000005442540000056135900033741000000-3000026870000-43496000-712000000-1840000081200002685200001020000002999220000009030005373000-4255600000000256309000-103195900000018420000-10338010000000000002137400000000000000000000090300019953190000-20157900000094000002986028000000000000002995428000-541630000-5416300015025500096092000Items that will not be reclassified to profit or loss-150000-150000Items that will not be reclassified to profit or loss-300000-30000000Items that will be reclassified to profit or loss10020001002000Items that will be reclassified to profit or loss64000064000000852000340000